Capitalizing on New Opportunities for Stem Cell Products1. EXECUTIVE SUMMARY
REPORT #09-002
Capitalizing on New Opportunities
Overview
April 2009
for Stem Cell Products
Print: $3,200 $2,700
Electronic (.pdf): $5,200 $4,500
This pre-publication discount price is only available until May 17, 2009!
Overview
& Key Findings
Methodology
of products purchased from each major supplier), and plan
As a result of the March 9, 2009 reversal of the 2001 restrictions
a long-term strategy to secure your leading position in this
on federal funding of human embryonic stem cell research,
expanding market. For tactical planning purposes, the report
suppliers of stem cell related products are in need of a fast,
includes detailed market share estimates across major stem cell
accurate assessment of new opportunities in the stem cell
product categories by market segment, geographic region and top
products market. Additionally, given that practical stem cell-
suppliers. Combined with data on scientists’ stem cell research
based therapies can take years to develop, suppliers will benefit
budgets and expected changes in spending through 2011,
from a clear understanding of the wide range of products that
suppliers can use this information to anticipate areas of growth
support basic stem cell research already in progress. Capitalizing
and product saturation.
on New Opportunities for Stem Cell Products, BioInformatics
LLC’s latest report, will enable suppliers to respond quickly to
Report Highlights
One key finding in this report was that only 14% of the scientists
a market disrupted by an Executive Order, and to gain a better
surveyed indicated that the lifting of the restrictions on federal
understanding of how today’s stem cell products market is
funding for human embryonic stem cell research will affect their
driven by long-term stem cell research requirements.
decision as to what types of stem cells
Contact us at to use in their research; the majority
In Capitalizing on New Opportunities for Stem Cell Products,
703.778.3080 x13 of study will still involve using adult
we surveyed close to 500 scientists from around the world
stem cells, suggesting that these
about their current—and planned—areas of research, usage of
to review the study
cells will continue to play a major
stem cell products and preferred suppliers. This report will help
questionnaire role in advancing the field of stem
you to determine areas poised for growth (i.e., media, sera,
cell research. Furthermore, almost
supplements and cell lines) in the stem cell research products
half of the scientists indicated that the goal of their research
market, identify potential key competitors (including percentage
Analyst Expertise
is understanding basic biology of stem cells, as opposed to
developing cell-based therapies, drug discovery or preclinical/
Report Objectives clinical trials. More specifically, we have found that 75% of
respondents are focused on stem cell differentiation, which has
tremendous implications for product development. (Please see
• Identify new/expanding stem cell research opportunities page 2 for supporting data.)
as a result of the ban on federal funding for research on
human embryonic stem cells being lifted This analysis also provides suppliers with critical insight into
optimizing product offerings based upon scientists’ level of
• Estimate market share and project growth of stem cell
satisfaction with stem cell culture products and the level of
research products by market segment and geographic
Company Information
interest in developing integrated stem cell product lines and
region
services. The scientists surveyed share their opinions on what
• Estimate market share of top suppliers by stem cell new product/technologies would be most beneficial to their
research product category (i.e., media, sera, supplements, research. Additionally, the report reveals what channels stem cell
and cells) scientists use to access information relevant to their research,
which in turn can be used by suppliers to more effectively target
• Learn types and species of stem cells scientists intend
their products and services.
to use
• Determine level of satisfaction with stem cell media and The March 2009 policy change will have implications for life
unmet needs with respect to stem cell products and cell science suppliers as academic scientists consider conducting
lines research on previously unavailable human embryonic stem cell
BioInformatics
• Anticipate change in spending on stem cell products and
Order Form
cell lines over the next two to three years (through 2011) market insights from gene to drug
2111 Wilson Blvd
• Project market size for stem cell products through 2011
Suite 250
• Uncover interest in integrated stem cell workflow products
Arlington, VA 22201
and services
www.gene2drug.com
703.778.3081 (fax)
Capitalizing on New Opportunities for Stem Cell Products Executive Summary Page 1 of 7
©2009 BioInformatics, LLC
2. Overview (continued) Methodology
lines. But while the excitement about human embryonic stem
Capitalizing on New Opportunities for Stem Cell
cell research is on the rise, including in the pharmaceutical and
Products is based on responses to a 60-question
Overview
biotech industry, suppliers need actionable information about
online survey conducted by BioInformatics, LLC.
scientists’ plans to pursue research using all types of cell lines in
The questionnaire was completed by nearly 500 life
a global market. This report provides insights into the origins and
scientists worldwide who currently perform stem
sources of stem cells currently used in the lab (adult, embryonic
cell research or plan to perform stem cell research
and induced pluripotent) and those likely to be used over the
between March 23 and April 6, 2009. The questionnaire
next several years—in addition to differentiated cell types and
consisted of 39 closed or partially close-ended
associated diseases under investigation—allowing suppliers to
questions and 21 open-ended questions designed to
anticipate the types of stem cell culture products scientists will
encourage participation and to meet objectives of the
need to purchase. Moreover, this report includes a supplemental
study.
section about scientists who plan to conduct stem cell research
& Key Findings
Methodology
in the near future to help companies better anticipate the stem
The questions were answered by highly-qualified
cell product needs of new customers.
members of The Science Advisory Board™.
BioInformatics sponsors The Science Advisory
Capitalizing on New Opportunities for Stem Cell Products
Board™, an online community of more than 43,000
provides a roadmap for stem cell product suppliers to help
scientists engaged in basic biological research, clinical
navigate a landscape that is poised for change—and growth. This
research and drug discovery and development. These
analysis was designed to guide suppliers in redirecting resources
experts have agreed to make themselves available
to new areas and markets, and to help refine current offerings
to answer questions including emerging areas of
by making them more responsive to scientists who are already
research, the tools and techniques used in their labs,
engaged in stem cell research.
and their satisfaction with their current suppliers.
Report Highlights
Key Findings
Theme That Best Reflects The Goal of Their Research Feature(s) of Stem Cells Studied/Employed
Employing stem
75%
Differentiation
cells in
preclinical/
clinical trials 41%
Pluripotency marker(s)
8%
Analyst Expertise
37%
Self-renewal
Developing cell-
based therapies
Understanding 37%
Propagation
using stem cells
the basic biology
23%
of stem cells
45% 30%
Drug screening toxicity
Reprogramming 26%
Using stem cells
23%
Epigenetics
in drug discovery
and/or
Company Information
development 4%
Other
24%
Is Your Decision as to What Types of Stem Cells to Use Affected by the Embryonic stem cells in
Lifting of the US Restrictions on Federal Funding for Human Embryonic place of adult stem cells
and/or induced
Stem Cell Research?
pluripotent stem cells
No
8%
56%
Yes, because I will Embryonic stem cells in
47%
14% now study... addition to adult stem
45% cells and/or induced
Order Form
pluripotent stem cells
13%
17% Additional embryonic
stem cell lines
Don't know/
Not not sure
applicable
Capitalizing on New Opportunities for Stem Cell Products Executive Summary Page 2 of 7
©2009 BioInformatics, LLC
3. Report Highlights
Capitalizing on New Opportunities for Stem Cell Products
REPORT #09-002
Overview
Section 1. Analysis • Source and type of stem cell lines plan to use two to
three years from now (2010 and 2011)
Market Size and Share and Market Growth Potential
• Impact on research of lifting US restrictions on federal
• Estimated market share for stem cell research products
funding of embryonic stem cells
by market segment and geographic region
• Differentiated cell types that were/are/will be the focus
• Estimated market share of top suppliers by stem
of stem cell research for 2008, 2009, and two to three
cell research product category (i.e., media, sera,
years from now (2010 and 2011)
supplements, and cells)
& Key Findings
Methodology
• Diseases that are the focus of stem cell research by type
• Projected growth of stem cell research products market
of stem cell
by market segment and geographic region
• Top scientific journals respondents rate as most critical
• Anticipated stem cell research budgets for 2009 by
to their stem cell research
market segment and geographic region
• Critical stem cell conferences
• Expected change in spending on stem cell products
and cell lines over the next two to three years (through
2011) Stem Cell Culture Products: Top Suppliers and Budgets
• Suppliers from whom respondents purchase stem cell
culture products
Report Highlights
Frequently Asked Questions (related to):
• Percent of stem cell culture product purchases made
• Products needed to support scientists’ current stem cell
from leading suppliers
research
• Estimated 2008 budget for stem cell culture products
• Cell types and disease that are/will be the focus of stem
cell research • Percent of 2008 budget spent on stem cell media, sera,
and supplements
• Use of embryonic versus induced pluripotent cells for
specific applications • Estimated 2009 budget that will be dedicated to stem cell
culture products and stem cell lines
• Unmet product needs and product differentiation
strategies • Percent of 2009 budget that will be spent on stem cell
Analyst Expertise
media, sera, and supplements
• New product and/or service development opportunities
• Expected change in expenditures on stem cell media,
• Best channels by which to communicate with and
sera, and supplements over the next two to three years
market to stem cell researchers
(2010 and 2011)
Stem Cell Media: Usage, Product Features and Special
Section 2. Methodology & Demographics Requirements
• Objectives • Types of media used to grow and culture stem cells
• Questionnaire design • Percent of media that is custom vs. off-the-shelf
Company Information
• Survey population • Estimate of stem cell culture media used per month in
2008
• Estimate of stem cell culture media expected to be used
per month in 2009
Section 3. Presentation of the Survey Data:
• Expected change in stem cell culture media usage for
Respondents Conducting Stem Cell Research two to three years from now (2010 and 2011)
Research Overview and Applications
• Importance of xeno-free and animal-free types of stem
• Length of time conducting research cell culture media
• Goals of stem cell research • Advantages of stem cell culture media from primary
supplier
• Features of stem cells studied
Order Form
• Satisfaction with features of stem cell culture media from
• Source, type, and number of different stem cell lines
primary supplier
used in 2008
• Requirements for GMP conditions for stem cell culture
• Source, type, and number of different stem cell lines
products
expected to be used in 2009
Capitalizing on New Opportunities for Stem Cell Products Executive Summary Page 3 of 7
©2009 BioInformatics, LLC
4. Report Highlights (continued)
Capitalizing on New Opportunities for Stem Cell Products
REPORT #09-002
Overview
Stem Cells: Sources, Budgets, and Special Requirements Additional Analysis by:
hoose
Why C port?
• General sources from which respondents acquire • Market segment
e
This R
stem cells • Geographic region
) 5
age
• Percent of stem cell purchases made from major sources
(see p
• Years of experience
in 2008
• Stem cell type
• Percent of stem cell purchases expected to be made from
• Research focus
major sources in 2009
& Key Findings
Methodology
• Lab size
• Expected changes in the percent of stem cell purchases
expected to be made from commercial suppliers over the
next two to three years (2010 and 2011)
• Commercial suppliers and/or national bank/repositories
Section 4. Appendices
from which respondents currently purchase stem cells
Appendix A. Respondents Planning to Conduct Stem Cell
• Percent of stem cell purchases made from commercial
Research
suppliers and/or national bank/repositories
• Time frame that respondents plan to begin stem cell
• Estimated 2008 budget for stem cell lines
research
• Estimated 2009 budget that will be dedicated to stem cell
Report Highlights
• Sources of funding that will support future stem cell
lines
research
• Reasons why respondents acquire stem cells from their
• Anticipated annual budget for stem cell culture products
primary suppliers
and stem cell lines
• Percent of stem cells grown on feeders and sources of
• Sources and types of stem cells respondents plan to use
feeder cells
in their research
• Use of 3-D cell culture in stem cell research
• Differentiated cell types that will be the focus of stem
• Reasons for interest in 3-D cell culture for stem cell cell research
research
• Diseases that will be the focus of stem cell research by
Analyst Expertise
cell type
Supporting Products, Technologies, and Services • Sources from which respondents plan to acquire
stem cells
• Techniques respondents use to identify differentiated cell
types derived from stem cells
• Major disadvantages of techniques used to identify Appendix B. Verbatim Responses to Questions
differentiated cell types derived from stem cells
• Do you think your stem cell research will change due
• Primary supplier of consumable products used to to the lifting of US restrictions on federal funding
perform techniques for identifying differentiated cell for human embryonic stem cell research by the new
types derived from stem cells presidential administration? Why or why not?
Company Information
• Stem cell-specific kits or panels currently used and • Like many stem cell pioneers, Ian Wilmut, the creator of
planned to use in the next 12 months Dolly the sheep, has embraced an alternative approach.
Are induced pluripotent stem cells the beginning of the
• Stages of stem cell workflow processes with which
end for embryonic cloning? Why or why not?
respondents are involved
• Stage of stem cell workflow that respondents would
most like a new product/technology to facilitate their
research
• Types of stem cell-related services that respondents
would be most interested in obtaining from suppliers
.
Order Form
Capitalizing on New Opportunities for Stem Cell Products Executive Summary Page 4 of 7
©2009 BioInformatics, LLC
5. Other Recent Publications*
Life Science Marketing
Overview
#09-001 Prospering in a Down Market: Strategies for Life Science Suppliers March 2009 159 Pages
#08-047 The Brave New World of Scientific Publishing November 2008 154 Pages
#08-019 Enabling Discovery: The 2008 Life Science Industry Awards June 2008 101 Pages
TM
#08-008 Instrumentation Service Contracts: Opportunities for Differentiation July 2008 136 Pages
#08-007 Protein Research: Strategies for Marketing to Chemists and Biologists September 2008 123 Pages
#08-006 Understanding Switching Dynamics: Maximizing Customer Retention in the Life Science March 2008 173 Pages
#08-004 Life Science Product Catalogs: Techniques to Increase Sales March 2008 92 Pages
& Key Findings
Methodology
#08-003 Conference & Exhibit Strategies in the Life Sciences: What’s Working Now February 2008 135 Pages
#08-002 Advertising to Life Scientists: Resolving the Print vs. Online Dilemma February 2008 105 Pages
#08-001 Marketing to Life Scientists: Capturing Customers’ Attention in Applied Markets January 2008 156 Pages
* See Web site www.gene2drug.com for a complete listing.
With hundreds of stem cell products market reports
to choose from, why choose ours?
Report Highlights
The design and analysis of Capitalizing on Carefully Selected Survey Participants
New Opportunities for Stem Cell Products When others promote results from their online surveys,
they fail to mention the uncontrolled nature of their
was spearheaded by BioInformatics LLC’s Vice
broadcast email invitations. To provide you with the most
President of Advisory Services Tamara Zemlo,
valid and accurate results possible, the respondents to our
Ph.D., MPH, who has been the lead analyst on
surveys are members of our unique online panel—The
over 80 syndicated market research reports. For
Science Advisory Board—which consists of more than
this study, Dr. Zemlo consulted with multiple 43,000 verified life science and biomedical professionals
stem cell products vendors to optimize the
Analyst Expertise
who have agreed to take part in our surveys, focus groups
relevance of this study with regards to the and other market research activities. These respondents
current stem cell research market. are carefully selected based on their professional
qualifications, market segments and geographic
regions—we can even select them based on the products
Sources of Independent, Unbiased Research
they use and their preferred suppliers.
Unlike reports from other firms that are based on an
analyst’s subjective summary of information from publicly
available sources, our reports are based on the results
Don’t settle for an imitation. Invest in the most
of detailed surveys of hundreds—even thousands—of
direct source of information from the scientists
scientific and medical professionals who buy your
Company Information
who buy your products, and the expert team that
products.
has been monitoring your clients since 1994.
Developed by a Team of Experts
Complimentary Consulting Provided
Our questionnaires are developed by a multi-
disciplinary team of scientists, industry veterans and With your purchase, we offer one free hour of consultation
market research experts with years of experience. These with our talented team of scientific and business analysts
professionals understand that survey questions need to who created the report. During this consultation, we can
be asked in a way that ensures the answers will directly answer any questions you may have about the survey
address the business challenges you face. Once the survey results and what we believe to be the significant trends
data is collected, this same team creates a unique report affecting the market.
that presents the reader with a thorough understanding of
Custom Analysis & Research Available
the topic and the scientific and business implications of
Order Form
the results based on sophisticated statistical analytics. If you’d like to delve deeper into the data from a study,
we can always perform custom cross-tabulations or other
analysis on your behalf. We can even pose follow-up
questions to respondents who answered in a particular
way or conduct a custom study to extend your knowledge.
Capitalizing on New Opportunities for Stem Cell Products Executive Summary Page 5 of 7
©2009 BioInformatics, LLC
6. About BioInformatics, LLC Our strength lies in our ability to integrate our understanding of
science and medicine with cutting-edge market research techniques.
As one of the first firms to recognize how the World Wide Web has
Since our inception in 1994, BioInformatics has provided critical
transformed market research, BioInformatics formed The Science
market intelligence to leading companies serving the life science,
medical device and pharmaceutical industries. We support clients Advisory Board. Launched in 1997, this global community currently
Overview
across the entire market spectrum—from scientific research to consists of more than 43,000 life science researchers, physicians
diagnostics and therapeutics—providing high-level management with and biomedical professionals who convene regularly via the Web to
market insights from gene to drug. voice their opinions on a wide variety of issues relating to biomedical
research and clinical technologies. Clients tap into this panel of
Our multi-disciplinary team of scientific experts and business experts and receive answers to their critical marketing questions in
analysts creates value for our clients by combining extensive industry days, rather than weeks. In addition to providing real-time insights
knowledge and experience. We offer a variety of products and into the perceptions of the market, posing questions to The Science
services that enable executives to see themselves, their market and
Advisory Board offers substantial cost savings over gathering
their competitors through the eyes of the most important information
information via traditional market research techniques.
source of all—customers. We can precisely meet the needs of our
& Key Findings
Methodology
clients through the most appropriate mix of research methodologies,
BioInformatics offers both published reports and custom research
including:
services. Published reports allow marketing professionals to share in
• Online Surveys
the results of broad-based market studies that provide access to high
• Online Focus Groups
quality research at an affordable price. Our custom research is tailored
• Mail Surveys
to the specific needs of the company’s executive management. For
• Telephone Interviews
more information about BioInformatics’ product and service offerings,
please visit our Web site at www.gene2drug.com, call 703.778.3080 or
email info@gene2drug.com.
Our Valued Clients
Report Highlights
Biotechnology/Life Science Eppendorf Plexagen Diagnostics Ortho-Clinical Diagnostics Phillip Johnson & Associates
454 Eurogentec Post Genome Institute Radiometer America PA Consulting
AbCam Expression Pathology Promega Tektronix Perry Ballard
Accelrys Fermentas Protein Forest Piper Jaffray
Pharmaceuticals
Affymetrix Fluidigm Proteome Systems Ruder Finn
Agencourt Bioscience GE Healthcare Qbiogene Abbott Laboratories Scherago International
Agilent Technologies Gen-Probe QIAGEN Amgen Select Equity Group
American Type Culture Gene Codes R & D Systems AstraZeneca Stephan & Brady
Collection Gene Logic Ribomed Biotechnologies Aventis The Strategy Works
Anachem Gene Therapy Systems Rosetta Biosoftware Baxter Healthcare UBS Warburg
Antibodies By Design Gentra Systems Sachem Bayer
Apple Computer Publishers & Associations
GenVault Corporation Sarstedt Boehringer Ingelheim
Applied Biosystems Pharmaceuticals
Genzyme Sandia National Laboratories Academic Press
Analyst Expertise
Applied Precision Cardinal Health
Guava Technologies SAS Institute American Academy of
Axxora Centocor Pediatrics
Helicos BioSciences Schott Nexterion
BD Biosciences Hoechst Marion Roussel AAAS/Science
Hewlett-Packard Sequenom
Beckman Coulter ICN Pharmaceuticals American Medical Association
High Throughput Genomics Serologicals
Biacore Janssen Pharmaceutica American Society for Cell
Hitachi Instruments Serotec
Biology
Bio-Rad Laboratories Merck
Hybrigenics Sigma-Aldrich
American Society for
Bioneer Novartis Pharmaceuticals
Hyseq Solexa
Microbiology
Biotage Novo Nordisk
IBM Life Sciences SomaLogic
American Society of Human
Pharmaceuticals
BioTrove Illumina Source Precision Medicine
Genetics
Pfizer
Blue Heron Biotechnology Immunotech Stratagene
BioTechniques/Eaton
Schering-Plough
Caliper Technologies InforMax Stressgen Biotechnologies
Publishing
Callida Genomics Integrated DNA Technologies Takara Mirus Bio
Blackwell Publishing
Company Information
Professional Services
Cambrex Bio Science Invitrogen Tecan
Cold Spring Harbor
& Finance
Carl Zeiss JRH Biosciences The Jackson Laboratory
Laboratory Press
Adjuvant Partners
Cell Signaling Technology Kirkegaard & Perry Thermo Fisher Scientific
Elsevier
Adventus Research
Celliance Laboratories Thomas Scientific
Federation of Amer. Societies
Agency.com
Charles River Laboratories Kodak Scientific Imaging Tocris Cookson
for Experimental Biology
Anvil Group
ChromaVision Medical Leica Microsystems Transgenomic
Harvard University Medical
Atlas Venture
Systems LI-COR UVP
School
Battelle Memorial Institute
Cipher Systems LION bioscience Varian
John Wiley & Sons
BioOnline
Clontech Laboratories Lonza VWR International
Mary Ann Liebert Publishers
Citadel Investment Group
Corning Luminex Vysis
Nature Publishing Group
Doran Media Services
DAKO MDS Sciex Waters
New England Journal of
Fidelity Management and
DNAStar Mettler-Toledo AutoChem Whatman
Medicine
Research
Dow Corning Millipore
Society for Neuroscience
Foley & Lardner
Dynal Biotech MiraiBio Medical Diagnostics
Springer-Verlag
Gerson Lehrman Group
eBIOINFORMATICS Molecular Devices Applied Imaging
Stanford University High Wire
HSBC Securities
Edge Biosystems MWG Biotech Ciba Corning Diagnostics
Order Form
Press
Infotrieve
Eksigent Technologies New England Biolabs Dade Behring
Thomson ISI
Innovative Marketing Group
EM Separations Technology NuGEN Technologies Diagnostic Products
Wolters Kluwer
McKinsey & Co.
EMD Biosciences Ovid Technologies Diametrics Medical
Nathan Associates
Entelechon Pall Life Sciences Hewlett-Packard Medical
National Research Council of
Epigenomics Percival Scientific Products
Canada
Epitomics PerkinElmer Life Sciences LifeScan
Novintel
Epoch Biosciences Photometrics Mallinckrodt
Capitalizing on New Opportunities for Stem Cell Products Executive Summary Page 6 of 7
©2009 BioInformatics, LLC
7. BioInformatics
REPORT #09-002 market insights from gene to drug
Capitalizing on New Opportunities for Stem Cell Products
Overview
PRE-PUBLICATION DISCOUNT PRICES are only available until May 17, 2009!
Print Copy—$3,200 Now $2,700!
Electronic Copy (includes one print copy)—$5,200 Now $4,500!
Ordering Information Electronic Copy
To place an order, fill out this form and mail it to BioInformatics, LLC or fax This format allows an unlimited number of users within your company
it to 703.778.3081. Alternatively, you may submit your order by emailing to access the report regardless of geographic location. You may place the
sales@gene2drug.com, calling 703.778.3080 or visiting electronic copy (PDF) on your secure, corporate intranet or share it with
& Key Findings
Methodology
www.gene2drug.com/order/201/. co-workers via email. In addition to providing greater accessibility, the
electronic copy allows you to easily navigate the document with the help
Payment must be made within 30 days and in U.S. dollars. of bookmarks, quickly search key words or phrases and print out any page.
BioInformatics’ Federal Tax ID #: 54-2001907. One print copy of the report is also provided at no additional cost.
Credit Card Data Set
You may charge your order to American Express, MasterCard, Visa, To accommodate your unique needs, the raw data is also available. With
Diner’s Card or Discover. Please include your credit card account number, the data, you can analyze respondents’ answer choices in any way needed,
expiration date and signature. including cross-tabulations, correlations, etc. The data set is offered in two
formats: SPSS® Base or Microsoft® Excel, and may only be purchased in
Wire Transfers conjunction with the company-wide electronic copy of the report.
Wire transfers should be sent to: SunTrust Bank, 2121 15th Street, Arlington,
Report Highlights
VA 22201, SWIFT #SNTRUS3A, ABA #071000104, Account #702260169.
I wish to order the following format of REPORT #09-002,
Capitalizing on New Opportunities for Stem Cell Products
Discount Price
o Print Copy $2,700 $________
o Electronic Copy (.pdf, includes print copy) $4,500 $________
o Add Data Set Excel or SPSS (circle one) +$1,200 +$________
Additional print copies _____ x $300 each +$________
Analyst Expertise
Promo Code ___________ –$________
Shipping & Handling
+$________
(Add $15 for U.S., $50 for Int’l)
$________
Total
o Check Enclosed (Payable to BioInformatics, LLC)
Company Information
o Purchase Order # ________________________________________
Name
o Bill Me
Title
o Am Ex o MasterCard o Visa o Diner’s Card o Discover
Organization
/
Street Address Credit Card # Exp Date
(MM/YY)
City, State/Province, Postal Code Name on card _____________________________________________
Country
Order Authorized By:
Order Form
Phone Fax
__________________________________________________________
Signature Date
Email
BioInformatics, LLC
2111 Wilson Blvd., Suite 250 Arlington, VA 22201
Web: www.gene2drug.com • Phone: 703.778.3080 x13 • Fax: 703.778.3081 • Email: m.follin@gene2drug.com
Capitalizing on New Opportunities for Stem Cell Products Executive Summary Page 7 of 7
©2009 BioInformatics, LLC